Rheumatoid arthritis is a chronic autoimmune disorder resulting in synovial inflammation. Fibroblast activation protein (FAP) is overexpressed by fibroblastlike synoviocytes in arthritic joi'/> Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti-Fibroblast Activation Protein Antibody
首页> 外文期刊>The Journal of Nuclear Medicine >Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti-Fibroblast Activation Protein Antibody
【24h】

Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti-Fibroblast Activation Protein Antibody

机译:可以使用放射性标记的抗成纤维细胞活化蛋白抗体非侵入性地监测实验性关节炎的脂质体治疗

获取原文
           

摘要

id="p-2">Rheumatoid arthritis is a chronic autoimmune disorder resulting in synovial inflammation. Fibroblast activation protein (FAP) is overexpressed by fibroblastlike synoviocytes in arthritic joints. Radioimmunoimaging with an anti-FAP antibody might be used to monitor the response to therapy, thus enabling tailored therapy strategies and therapeutic outcomes. The aim of this study was to assess whether a radiolabeled anti-FAP antibody could be used to monitor the efficacy of treatment with long-circulating liposomes (LCL) containing prednisolone phosphate (PLP-LCL) in a mouse model of arthritis. >Methods: Collagen-induced arthritis (CIA) was induced in male DBA/1J mice. Mice were treated with a single injection (10 mg/kg) of PLP-LCL or empty LCL as a control. SPECT and CT images were acquired 24 h after injection of 99mTc-labeled succinimidyl-hydrazinonicotinamide (99mTc-S-HYNIC)-conjugated anti-FAP antibody 28H1 at 2, 5, and 9 d after treatment. The uptake of 99mTc-S-HYNIC-28H1 in all joints was quantified and correlated with macroscopic arthritis scores. >Results: Treatment of CIA with PLP-LCL significantly suppressed joint swelling. At just 1 d after treatment, the macroscopic arthritis scores had decreased by 50%. Scores decreased further, to only 10% of the initial scores, at 5 and 9 d after treatment. In contrast, macroscopic arthritis scores had increased up to 600% in untreated mice at 9 d after the injection of empty LCL. 99mTc-S-HYNIC-28H1 uptake ranged from 1.5 percentage injected dose per gram in noninflamed joints to 22.6 percentage injected dose per gram in severely inflamed joints. The uptake of radiolabeled 28H1 in inflamed joints (percentage injected dose) correlated with the arthritis score (Spearman ??, 0.77; P 0.0001). Moreover, the uptake of 99mTc-S-HYNIC-28H1 was slightly increased at 9 d after therapy but was not seen macroscopically, indicating that SPECT/CT imaging might be more sensitive than the macroscopic arthritis scoring method. >Conclusion: SPECT/CT imaging with 99mTc-S-HYNIC-28H1 specifically monitored the response to therapy, and tracer accumulation correlated with the severity of inflammation. In addition, SPECT/CT imaging was potentially more sensitive than the macroscopic arthritis scoring method. This study showed that SPECT/CT with 99mTc-S-HYNIC-28H1 could be used to noninvasively monitor the course of CIA in mice.
机译:id =“ p-2”>类风湿关节炎是导致滑膜炎症的慢性自身免疫疾病。成纤维细胞活化蛋白(FAP)在关节炎关节中被成纤维细胞样滑膜细胞过表达。带有抗FAP抗体的放射免疫成像可用于监测对治疗的反应,从而实现量身定制的治疗策略和治疗效果。这项研究的目的是评估在小鼠关节炎模型中,是否可以使用放射性标记的抗FAP抗体监测含有强的松龙磷酸酯(PLP-LCL)的长循环脂质体(LCL)的治疗效果。 >方法:在雄性DBA / 1J小鼠中诱发胶原诱导的关节炎(CIA)。用单次注射(10 mg / kg)的PLP-LCL或空LCL作为对照治疗小鼠。在注射 99m Tc标记的琥珀酰亚胺-羟基壬二烟酰胺( 99m Tc-S-HYNIC)缀合的抗FAP抗体28H1后24小时,获得SPECT和CT图像治疗后5、9 d。量化所有关节中 99m Tc-S-HYNIC-28H1的摄取并与宏观关节炎评分相关。 >结果:用PLP-LCL治疗CIA可显着抑制关节肿胀。治疗后仅1天,宏观关节炎评分降低了50%。在治疗后第5天和第9天,评分进一步下降,仅为初始评分的10%。相比之下,空LCL注射后第9天,未经治疗的小鼠的宏观关节炎评分增加了600%。 99m Tc-S-HYNIC-28H1的摄取范围从非发炎关节的每克注射剂量的1.5%到严重发炎关节的每克注射剂量的22.6%。炎性关节中放射性标记的28H1的摄取(注射剂量的百分比)与关节炎评分相关(Spearman ??,0.77; P <0.0001)。此外,治疗后9 d, 99m Tc-S-HYNIC-28H1的摄取略有增加,但在肉眼看不到,表明SPECT / CT成像可能比宏观关节炎评分方法更敏感。 。 >结论:使用 99m Tc-S-HYNIC-28H1进行SPECT / CT成像可专门监测对治疗的反应,示踪剂蓄积与炎症的严重程度相关。此外,SPECT / CT成像可能比宏观关节炎评分方法更敏感。这项研究表明,带有 99m Tc-S-HYNIC-28H1的SPECT / CT可用于无创监测小鼠CIA的病程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号